key: cord-0752868-fh8meqrw authors: Ioannidou, Loukia; Dettoraki, Athina; Noni, Maria; Koukou, Dimitra‐Maria; Michalopoulou, Aikaterini; Botsa, Evanthia; Kapsimali, Zoey; Michos, Athanasios; Spoulou, Vana; Pergantou, Helen; Kanaka‐Gantenbein, Christina title: Pulmonary embolism in adolescent with COVID‐19 during aromatase inhibitor therapy date: 2022-04-26 journal: Pediatr Pulmonol DOI: 10.1002/ppul.25944 sha: d68e1dcb105fa5cd315a0cff3a4dcb3e417a4df6 doc_id: 752868 cord_uid: fh8meqrw Our case underlines the fact that pediatric patients with COVID‐19 could be in risk of developing severe VTE, including PE, especially in the presence of underlying risk factors that enhance the thrombotic mechanisms of SARS‐CoV‐2. Clinical suspicion should be high in specific age groups, like adolescents, and for certain therapies which are used in these populations. Further studies and updated recommendations regarding VTE risk assessment in children and adolescents are needed while COVID‐19 is still on its ride This article is protected by copyright. All rights reserved. To the Editor, Thrombotic complications associated with SARS-CoV-2 infection have been quite uncommon in children and adolescents with COVID-19 who do not develop multisystem inflammatory syndrome. 1 We report a case of an adolescent boy with COVID-19 who presented with extended deep vein thrombosis (DVT) resulting in pulmonary embolism (PE), managed in intensive care unit, while he was on treatment with anastrozole, an aromatase inhibitor (AI), whose thromboembolic risk has not been thoroughly studied in pediatric populations. The 15-year-old male presented to our emergency department with the diagnosis of right external iliac vein's DVT, as depicted in magnetic resonance imaging (MRI) of the hip (Figs. 1A and 1B), performed after orthopedic referral, due to a four-day history of gradually progressive pain and swelling of the right lower limb. With regards to his medical history, the boy had short stature and was receiving anastrozole over the last two years for height increase. On admission, the adolescent exhibited pain in the right hip with limited mobility of the joint and edema of the right knee, while body temperature was 38.9 o C and rest of vital signs within normal range. A triplex ultrasound of the right lower extremity followed, demonstrating that the DVT was extending further down to great saphenous and popliteal vein. Initial This article is protected by copyright. All rights reserved. Article anticoagulation treatment consisted of subcutaneous low molecular weight heparin (LMWH) i.e., tinzaparin in therapeutic dose. Few hours after admission, the boy developed hypotension with low diastolic blood pressure (25 mmHg), tachycardia (125 beats/min) and drop of oxygen saturation to 94%. Urgent computed tomography pulmonary angiogram (CTPA) revealed a big embolus of 3 cm longitudinal diameter in the left pulmonary artery, establishing the diagnosis of PE. (Figs. 1C and 1D) . Along with this finding, initial laboratory results were finalized (Table 1) , including nasopharyngeal swab for SARS-CoV-2 RT-PCR, which was positive for COVID-19. The boy was transferred to the COVID-19 pediatric intensive care unit where he received oxygen supply and intravenous (IV) dexamethasone 0.15 mg/kg (max 6 mg/day). He continued on subcutaneous tinzaparin and was supplemented with a single dose of IV antithrombin (AT) concentrate due to low AT levels, resulting in immediate response (values from 36% to 125%). There was no need for intubation or systematic thrombolysis. High temperature subsided 24 hours later, oxygen was gradually weaned off and the patient stepped down to the COVID-19 pediatric ward after 72 hours. A total of ten days of IV dexamethasone was completed and LMWH was substituted by oral warfarin after three weeks. The patient was discharged on day 34 with oral therapeutic anticoagulation whereas anastrozole treatment was ceased. Hemostatic parameters were regularly monitored post-discharge, as summarized in Table 1 . Further investigation with genetic testing for hereditary thrombophilia was negative and follow-up imaging showed radiographic thrombus resolution. Pulmonary embolism in our patient was secondary to venous thromboembolism (VTE) affected the lower limb and caused by the Accepted Article hypercoagulability state induced by the virus. Deranged hemostatic parameters i.e., prolongation in prothrombin time, elevated D-dimers and high levels of factor VIII, confirmed the presence of COVID-19 associated coagulopathy, given that these hemostatic alterations are typical of the entity. 2 Systematic thrombolysis was not required in our case, despite the presence of initial hemodynamic instability. In addition to therapeutic anticoagulation and treatment with steroids, management as well included supplementation with IV antithrombin concentrate, due to patient's acquired antithrombin deficiency, a serious prothrombotic condition present in Nevertheless, apart from the procoagulant effect of COVID-19, treatment with anastrozole could further enhance the thrombotic risk. AI therapies block the aromatase mediated synthesis of estrogens from androgens and are used in adolescent boys with short stature, aiming at greater height potential by delaying the epiphysial maturation, given the fact that the ultimate fusion of growth plates is estrogendependent. Although their adverse effects have been poorly assessed in pediatric populations, there have been suggestions that such therapies could cause VTE in pubertal boys. 4 The potential mechanism is that the mitigation of androgens' conversion to estrogens could result in increased testosterone concentration which, in turn, may lead to secondary erythrocytosis, increasing the risk of thromboembolic events. Finally, there is an additional suggested mechanism through which AI potentialize SARS-CoV-2 complications. To date, there is wide evidence that one of the key factors of SARS-COV-2 susceptibility is the overexpression of transmembrane serine protease 2 (TMPRSS2), as the last facilitates SARS-COV-2 cell entry by priming the virus spikes for recognition by its cell receptor, the angiotensin This article is protected by copyright. All rights reserved. Article converting enzyme 2 receptor. 5 TMPRSS2 expression is positively regulated by androgens and, in this context, it has been postulated that the androgen accumulation occurring in patients receiving AI treatment could potentially promote SARS-CoV-2 infectivity and complications, through the androgen-driven upregulation of TMPRSS2. 6 Our case underlines the fact that pediatric patients with COVID-19 could be at risk of developing severe VTE, including PE, especially in the presence of underlying risk factors that enhance the thrombotic mechanisms of SARS-CoV-2. Clinical suspicion should be high in specific age groups, like adolescents, and for certain therapies which are used in these populations. Further studies and updated recommendations regarding VTE risk assessment in children and adolescents are needed while COVID-19 is still on its ride. EPICO-AEP Working This article is protected by copyright. All rights reserved. Accepted Article Group Coagulopathy in COVID-19 Antithrombin III deficiency-induced coagulopathy in the context of COVID-19: a case series Use of aromatase inhibitors in children and adolescents: what's new? The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment Repurposing existing drugs for COVID-19: an endocrinology perspective Division of Infectious Diseases, First Department of Pediatrics Aghia Sophia' Children's Hospital, Athens, Greece 4. Division of Endocrinology The authors would like to acknowledge the Pediatric Intensive Care Unit of "P & A The authors declare that they have no conflict of interest.